We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Provides Guidance on Chronic Hepatitis C Trials
EMEA Provides Guidance on Chronic Hepatitis C Trials
May 28, 2008
Sponsors of initial clinical trials of treatments for chronic hepatitis C (CHC) are advised to enroll subjects who have not received standard-of-care treatment, have hepatitis C virus (HCV) genotype 1 infections and are not infected with advanced fibrosis or HIV, according to a draft guideline from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use.